Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ASCENDIS PHARMA A/S

(ASND)
  Report
Real-time Estimate Cboe BZX  -  10:23:02 2023-02-02 am EST
119.79 USD   -3.01%
01/18Tech Stocks Lead European Equities Modestly Higher in Wednesday Trading
MT
01/17Pharma Stocks Lead European Equities Higher in Tuesday Trading
MT
01/17SVB Securities Adjusts Price Target on Ascendis Pharma to $163 From $148, Maintains Outperform Rating
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/27/2023 01/30/2023 01/31/2023 02/01/2023 02/02/2023 Date
122.5(c) 120.8(c) 124.08(c) 123.5(c) 120.98 Last
153 978 359 051 145 655 157 206 33 971 Volume
+0.80% -1.39% +2.72% -0.47% -2.04% Change
More quotes
Estimated financial data (e)
Sales 2022 45,8 M 50,0 M 50,0 M
Net income 2022 -530 M -578 M -578 M
Net cash position 2022 455 M 497 M 497 M
P/E ratio 2022 -11,8x
Yield 2022 -
Sales 2023 148 M 162 M 162 M
Net income 2023 -546 M -596 M -596 M
Net Debt 2023 83,1 M 90,7 M 90,7 M
P/E ratio 2023 -11,7x
Yield 2023 -
Capitalization 6 334 M 6 916 M 6 916 M
EV / Sales 2022 128x
EV / Sales 2023 43,4x
Nbr of Employees 639
Free-Float 10,3%
More Financials
Company
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology,... 
More about the company
Ratings of Ascendis Pharma A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about ASCENDIS PHARMA A/S
01/18Tech Stocks Lead European Equities Modestly Higher in Wednesday Trading
MT
01/17Pharma Stocks Lead European Equities Higher in Tuesday Trading
MT
01/17SVB Securities Adjusts Price Target on Ascendis Pharma to $163 From $148, Maintains Out..
MT
01/10BioAtla Sees Dosing of First Patient in Mid-Stage Part 2 Study in Soft Tissue Cancer Th..
MT
01/09Transcript : Ascendis Pharma A/S Presents at 41st Annual J.P. Morgan Healthca..
CI
01/09European Equities Begin Week With Sharp Rise
MT
01/09Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K
PU
01/08Ascendis Pharma Provides Update on Vision 3x3 Strategic Roadmap at 41st Annual J.P. Mor..
AQ
01/04Online Enrollment Now Open for Physicians Requesting Expanded Access to Ascendis Pharma..
AQ
01/03Ascendis Pharma A/s : Articles of Association - Form 6-K
PU
01/03Wells Fargo Boosts Price Target on Ascendis Pharma to $177 From $169, Keeps Overweight ..
MT
01/03Ascendis Pharma to Present at the 41st AnnualáJ.P. Morgan Healthcare Conference
AQ
2022Ascendis Pharma A/s : Articles of Association - Form 6-K
PU
2022After Seesaw Opening, European Equities Little Changed in Monday Trading
MT
2022Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K
PU
More news
News in other languages on ASCENDIS PHARMA A/S
01/18Les valeurs technologiques mènent les actions européennes en légère hausse dans les éch..
01/17Les valeurs pharmaceutiques mènent les actions européennes à la hausse dans les échange..
01/10BioAtla prévoit l'administration d'une dose à un premier patient dans le cadre d'une ét..
01/09Les actions européennes commencent la semaine avec une forte hausse
2022Après une ouverture en dents de scie, les actions européennes ont peu changé dans les é..
More news
Analyst Recommendations on ASCENDIS PHARMA A/S
More recommendations
ETFs positioned on ASCENDIS PHARMA A/SETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
ALPS Medical Breakthroughs ETF - USD2.97%1.04%United_States
Virtus LifeSci Biotech Products ETF - USD1.91%0.42%United_States
Global X Guru Index ETF - USD1.61%3.04%United_States
Mackenzie Maximum Diversification Developed...1.05%-0.74%Europe
Mackenzie Maximum Diversification All World...0.65%0.69%World
More ETFs positioned on ASCENDIS PHARMA A/S
Chart ASCENDIS PHARMA A/S
Duration : Period :
Ascendis Pharma A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASCENDIS PHARMA A/S
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 113,11 €
Average target price 146,94 €
Spread / Average Target 29,9%
EPS Revisions
Managers and Directors
Jan M°ller Mikkelsen President, CEO & Executive Director
Scott Thomas Smith Chief Financial Officer & Senior Vice President
Albert Cha Chairman
Birgitte Volck SVP, Head-Clinical Development & Medical Affairs
Kennett Sprog°e Senior Vice President, Head-Innovation & Research
Sector and Competitors
1st jan.Capi. (M$)
ASCENDIS PHARMA A/S1.12%6 916
VERTEX PHARMACEUTICALS11.88%81 440
REGENERON PHARMACEUTICALS, INC.5.06%80 956
WUXI APPTEC CO., LTD.15.90%40 901
BIONTECH SE-4.77%34 764
BEIGENE, LTD.15.61%26 436